StocksMedium•8 October 2026•
1 min read
Argenx Shares Plunge 18% Following Vyvgart Clinical Trial Halt
Key Facts
1Argenx shares dropped 18% after the company halted a late-stage clinical trial of its drug Vyvgart.
2The clinical trial was stopped due to lack of efficacy, wiping out the stock's year-to-date gains.
Argenx shares dropped 18% after the company halted a late-stage clinical trial of its drug Vyvgart. The Wall Street Journal reported that the trial was terminated due to a lack of efficacy in treating the targeted autoimmune conditions.
The significant price decline wiped out the stock's year-to-date gains. This late-stage trial failure impacts the company's valuation and future revenue projections within the biotechnology sector.